Mechanisms of dexamethasone-induced hypertension

Current Hypertension Reviews

Volumn 5, Issue 1, 2009, Pages 61-74

  Ong, Sharon L H ^a   Zhang, Yi ^a   Whitworth, Judith A ^a  

^a Australian National University   (Australia)

Author keywords

Dexamethasone induced hypertension; Glucocorticoid; Nitric oxide; Oxidative stress; Pathogenesis; Reactive oxygen species

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 20 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ADRENALIN; ADRENERGIC RECEPTOR; ANGIOTENSIN II; ARGININE; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; MIFEPRISTONE; NEOMYCIN; NEUROPEPTIDE Y; NITRIC OXIDE; NORADRENALIN; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROSTANOID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE; XANTHINE OXIDASE;

ADRENERGIC SYSTEM; CATECHOLAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG INDUCE HYPERTENSION; DRUG INDUCED DISEASE; DRUG INDUCED HYPERTENSION; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; HEMODYNAMICS; HUMAN; HYPERTENSION; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SODIUM RETENTION; VASOCONSTRICTION;

EID: 65949109908     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340209787314315     Document Type: Review

References (155)

1. Stewart PM, Walker BR, Holder G, O'Halloran D, Shackleton CH. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80: 3617-20.
2. Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991; 72: 1060-6.
3. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989; 7: 537-49.
4. Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens 1996; 14 (Suppl.): S37-41.
5. Li M, Wen C, Fraser T, Whitworth JA. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. J Hypertens 1999; 17: 419-26.
6. Moura AM, Worcel M. Anti-hypertensive action of the effects of spironolactone on the permeability of smooth muscles to Na+ and Rb+. J Physiol 1981; 77: A2-A3.
7. Grunfeld JP, Eloy L, Moura AM, Ganeval D, Ramos-Frendo B, Worcel M. Effects of antiglucocorticoids on glucocorticoid hypertension in the rat. Hypertension 1985; 7: 292-9.
8. Rebuffat AG, Tam S, Nawrocki AR, et al. The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol Cell Endocrinol 2004; 214: 27-37.
9. Bos AF, van Asselt WA, Okken A. Dexamethasone treatment and fluid balance in preterm infants at risk for chronic lung disease. Acta Paediatr 2000; 89: 562-5.
10. Hayamizu S, Kanda K, Ohmori S, Murata Y, Seo H. Glucocorticoids potentiate the action of atrial natriuretic polypeptide in adrenalectomized rats. Endocrinology 1994; 135: 2459-64.
11. Bengele HH, McNamara ER, Alexander EA. Natriuresis after adrenal enucleation: effect of spironolactone and dexamethasone. Am J Physiol Renal Physiol 1977; 233: F8-12.
12. Hu L, Zhang Y, Lim PS, et al. Apocynin but not L-arginine prevents and reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2006; 19: 413-8.
13. Ong SLH, Vickers JJ, Zhang Y, McKenzie KUS, Walsh CE, Whitworth JA. Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol 2007; 34: 517-9.
14. Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KUS, Whitworth JA. The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2004; 17: 260-5.
15. Okuno T, Suzuki H, Saruta T. Dexamethasone hypertension in rats. Clin Exp Hypertens 1981; 3: 1075-86.
16. Nakamoto H, Suzuki H, Kageyama Y, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A 1991; 13: 587-606.
17. Nakamoto H, Suzuki H, Kageyama Y, et al. Depressor systems contribute to hypertension induced by glucocorticoid excess in dogs. J Hypertens 1992; 10: 561-9.
18. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19: 567-74.
19. Gardiner SM, Kemp PA, March JE, Bennett T. Effects of dexamethasone and SB 209670 on the regional haemodynamic responses to lipopolysaccharide in conscious rats. Br J Pharmacol 1996; 118: 141-9.
20. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-8.
21. Handa M, Kondo K, Suzuki H, Saruta T. Dexamethasone hypertension in rats: role of prostaglandins and pressor sensitivity to norepinephrine. Hypertension 1984; 6: 236-41.
22. Russo D, Fraser R, Kenyon CJ. Dexamethasone therapy selectively increases the sensitivity to noradrenaline of the rat mesenteric circulation. J Hypertens Suppl 1989; 7: S126-7.
23. Russo D, Fraser R, Kenyon CJ. Increased sensitivity to noradrenaline in glucocorticoid-treated rats: the effects of indomethacin and desipramine. J Hypertens 1990; 8: 827-33.
24. Iijima F, Malik KU. Contribution of vasopressin in dexamethasone-induced hypertension in rats. Hypertension 1988; 11: I42-6.
25. Sato A, Suzuki H, Iwaita Y, Nakazato Y, Kato H, Saruta T. Potentiation of inositol trisphosphate production by dexamethasone. Hypertension 1992; 19: 109-15.
26. Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta T. Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension. J Hypertens 1994; 12: 511-6.
27. Stern N, Palant C, Ozaki L, Tuck ML. Dexamethasone enhances active cation transport in cultured aortic smooth muscle cells. Am J Hypertens 1994; 7: 146-50.
28. Pamnani MB, Clough DL, Haddy FJ. Altered activity of the sodium-potassium pump in arteries of rats with steroid hypertension. Clin Sci Mol Med Suppl 1978; 4: 41s-3s.
29. Sambhi MP, Weil MH, Udhoji VN. Pressor responses to norepinephrine in humans before and after corticosteroids. Am J Physiol 1962; 203: 961-3.
30. Lefer AM, Manwaring JL, Verrier RL. Effect of corticosteroids on the cardiovascular responses to angiotensin and norepinephrine. J Pharmacol Exp Ther 1966; 154: 83-91.
31. Haigh RM, Jones CT. Effect of glucocorticoids on alpha-1 adrenergic receptor-binding in rat vascular smooth muscle. J Mol Endocrinol 1990; 5: 41-8.
32. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991; 88: 385-9.
33. Kumai T, Asoh K, Tateishi T, et al. Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats. Life Sci 2000; 67: 1993-9.
34. Watanabe T, Noshiro T, Akama H, et al. Effect of dexamethasone on plasma free dopamine: dopaminergic modulation in hypertensive patients. Hypertens Res 1995; 18(Suppl 1): S197-8.
35. Kennedy B, Elayan H, Ziegler MG. Glucocorticoid hypertension and nonadrenal phenylethanolamine N-methyltransferase. Hypertension 1993; 21: 415-9.
36. Kennedy B, Ziegler MG. Cardiac epinephrine synthesis. Regulation by a glucocorticoid. Circulation 1991; 84: 891-5.
37. Adrian TE, Allen JM, Bloom SR, et al. Neuropeptide Y distribution in human brain. Nature 1983; 306: 584-6.
38. Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in the rat brain. Science 1983; 221: 877-9.
39. Gu J, Polak JM, Adrian TE, Allen JM, Tatemoto K, Bloom SR. Neuropeptide tyrosine (NPY) - a major cardiac neuropeptide. Lancet 1983; 1: 1008-10.
40. Lundberg JM, Terenius L, Hokfelt T, Goldstein M. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 1983; 42: 167-72.
41. Sundler F, Bottcher G, Ekblad E, Hakanson R. In: Colmers W and Wahlestedt C, Eds. The Biology of Neuropeptide Y and Related Peptides. Humana Press 1993; 157-96.
42. Haass M, Cheng B, Richardt G, Lang RE, Schomig A. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol 1989; 339: 71-8.
43. Pernow J, Lundberg JM. Modulation of noradrenaline and neuropeptide Y (NPY) release in the pig kidney in vivo: involvement of alpha 2, NPY and angiotensin II receptors. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 379-85.
44. Echtenkamp SF, Dandridge PF. Renal actions of neuropeptide Y in the primate. Am J Physiol Renal Physiol 1989; 256: F524-31.
45. Tanaka MDE, Mori MDH, Chujo MM, et al. Coronary vasoconstrictive effects of neuropeptide Y and their modulation by the ATP-sensitive potassium channel in anesthetized dogs. J Am Coll Cardiol 1997; 29: 1380-9.
46. Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 1984; 83: 519-25.
47. Corder R, Pralong F, Turnill D, Saudan P, Muller AF, Gaillard RC. Dexamethasone treatment increases neuropeptide Y levels in rat hypothalamic neurones. Life Sci 1988; 43: 1879-86.
48. Myrsen U, Ahren B, Sundler F. Dexamethasone-induced neuropeptide Y expression in rat islet endocrine cells. Rapid reversibility and partial prevention by insulin. Diabetes 1996; 45: 1306-16.
49. Myrsen-Axcrona U, Karlsson S, Sundler F, Ahren B. Dexamethasone induces neuropeptide Y (NPY) expression and impairs insulin release in the insulin-producing cell line RINm5F. Release of NPY and insulin through different pathways. J Biol Chem 1997; 272: 10790-6.
50. Wilding JP, Gilbey SG, Lambert PD, Ghatei MA, Bloom SR. Increases in neuropeptide Y content and gene expression in the hypothalamus of rats treated with dexamethasone are prevented by insulin. Neuroendocrinology 1993; 57: 581-7.
51. Tabarin A, Minot AP, Dallochio M, Roger P, Ducassou D. Plasma concentration of neuropeptide Y in patients with adrenal hypertension. Regul Pept 1992; 42: 51-61.
52. Brown MR, Fisher LA. Glucocorticoid suppression of the sympathetic nervous system and adrenal medulla. Life Sci 1986; 39: 1003-12.
53. Silvan G, Martinez-Mateos MM, Blass A, et al. The effect of long-term exposure to combinations of growth promoters in Long Evans rats: Part 1: Endocrine adrenal function. Anal Chim Acta 2007; 586: 246-51.
54. Rothschild AJ, Langlais PJ, Schatzberg AF, Walsh FX, Cole JO, Bird ED. Dexamethasone increases plasma free dopamine in man. J Psychiatr Res 1984; 18: 217-23.
55. Macefield VG, Williamson PM, Wilson LR, Kelly JJ, Gandevia SC, Whitworth JA. Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Blood Press 1998; 7: 215-22.
56. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719-34.
57. Eggena P, Barrett JD. Renin substrate release in response to perturbations of renin-angiotensin system. Am J Physiol Endocrinol Metab 1988; 254: E389-93.
58. Suzuki H, Handa M, Kondo K, Saruta T. Role of renin-angiotensin system in glucocorticoid hypertension in rats. Am J Physiol Endocrinol Metab 1982; 243: E48-51.
59. Ferrario CM, Chappell MC. In: Izzo Jr JL, Sica DA, and Black HR Eds. Hypertension Primer: the essentials of high blood pressure: basic science, population science and clinical management. Lippincott Williams Wilkins. 2008; 52-8.
60. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
61. Kimura S, Zhang G-X, Nishiyama A, et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005; 45: 438-44.
62. Murasawa S, Matsubara H, Kizima K, Maruyama K, Mori Y, Inada M. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension 1995; 26: 665-9.
63. Huang LQ, Whitworth JA, Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul Fibrinolysis 1995; 6: 438-45.
64. Roubert P, Viossat I, Lonchampt MO, et al. Endothelin receptor regulation by endothelin synthesis in vascular smooth muscle cells: effects of dexamethasone and phosphoramidon. J Vasc Res 1993; 30: 139-44.
65. Kanse SM, Takahashi K, Warren JB, Ghatei M, Bloom SR. Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. Eur J Pharmacol 1991; 199: 99-101.
66. Takahashi K, Suda K, Lam HC, Ghatei MA, Bloom SR. Endothelin-like immunoreactivity in rat models of diabetes mellitus. J Endocrinol 1991; 130: 123-7.
67. Borcsok I, Schairer HU, Sommer U, et al. Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. J Exp Med 1998; 188: 1563-73.
68. Tonolo G, Fraser R, Connell JM, Kenyon CJ. Chronic low-dose infusions of dexamethasone in rats: effects on blood pressure, body weight and plasma atrial natriuretic peptide. J Hypertens 1988; 6: 25-31.
69. Gardner DG, Hane S, Trachewsky D, Schenk D, Baxter JD. Atrial natriuretic peptide mRNA is regulated by glucocorticoids in vivo. Biochem Biophys Res Commun 1986; 139: 1047-54.
70. Garcia R, Debinski W, Gutkowska J, et al. Gluco- and mineralo-corticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochem Biophys Res Commun 1985; 131: 806-14.
71. Lachance D, Garcia R, Gutkowska J, Cantin M, Thibault G. Mechanisms of release of atrial natriuretic factor I. Effect of several agonists and steroids on its release by atrial minces. Biochem Biophys Res Commun 1986; 135: 1090-8.
72. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278: 456-9.
73. Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 1980; 77: 2533-6.
74. Russo-Marie F, Duval D. Dexamethasone-induced inhibition of prostaglandin production dose not result from a direct action on phospholipase activities but is mediated through a steroid-inducible factor. Biochim Biophys Acta 1982; 712: 177-85.
75. Falardeau P, Martineau A. Prostaglandin I2 and glucocorticoid-induced rise in arterial pressure in the rat. J Hypertens 1989; 7: 625-32.
76. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology 1986; 119: 62-9.
77. Nasjletti A, Erman A, Cagen LM, Baer PG. Plasma concentrations, renal excretion, and tissue release of prostaglandins in the rat with dexamethasone-induced hypertension. Endocrinology 1984; 114: 1033-40.
78. Codde JP, Beilin LJ. Dietary fish oil prevents dexamethasone induced hypertension in the rat. Clin Sci (Lond) 1985; 69: 691-9.
79. Zhang Y, Hu L, Mori TA, Barden A, Croft KD, Whitworth JA. Arachidonic acid metabolism in glucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol 2008; 35: 557-62.
80. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
81. Wen C, Li M, Whitworth JA. Role of nitric oxide in adrenocorticotrophin-induced hypertension: L-arginine effects reversed by N-nitro-L-arginine. Clin Exp Pharmacol Physiol 2000; 27: 887-90.
82. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
83. Mondo CK, Yang W-S, Su J-Z, Huang T-G. Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat. Clin Exp Hypertens 2006; 28: 499-509.
84. Wallerath T, Witte K, Schafer SC, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 1999; 96: 13357-62.
85. Wallerath T, Godecke A, Molojavyi A, Li H, Schrader J, Forstermann U. Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene. Nitric Oxide 2004; 10: 36-41.
86. Schmidt K, Werner ER, Mayer B, Wachter H, Kukovetz WR. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells. Biochem J 1992; 281 (Pt 2): 297-300.
87. Simmons WW, Ungureanu-Longrois D, Smith GK, Smith TW, Kelly RA. Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport. J Biol Chem 1996; 271: 23928-37.
88. Johns DG, Dorrance AM, Tramontini NL, Webb RC. Glucocorticoids inhibit tetrahydrobiopterin-dependent endothelial function. Exp Biol Med 2001; 226: 27-31.
89. Miao Y, Zhang Y, Lim PS, et al. Folic Acid prevents and partially reverses glucocorticoid-induced hypertension in the rat. Am J Hypertens 2007; 20: 304-10.
90. Wakabayashi Y, Yamada E, Yoshida T, Takahashi H. Deficiency of endogenous arginine synthesis provokes hypertension by exhausting substrate arginine for nitric oxide synthesis. Biochem Biophys Res Commun 1994; 205: 1391-8.
91. Li M, Fraser T, Wang J, Whitworth JA. Dexamethasone-induced hypertension in the rat: effects of L-arginine. Clin Exp Pharmacol Physiol 1997; 24: 730-2.
92. Azarov I, Huang KT, Basu S, Gladwin MT, Hogg N, Kim-Shapiro DB. Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation. J Biol Chem 2005; 280: 39024-32.
93. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
94. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-52.
95. Harrison DG, Gongora MC, Guzik TJ, Widder J. Oxidative stress and hypertension. J Am Soc Hypertens 2007; 1: 30-44.
96. Krug S, Zhang Y, Mori TA, et al. N-Acetylcysteine prevents but does not reverse dexamethasone-induced hypertension. Clin Exp Pharmacol Physiol 2008.
97. Zhang Y, Miao Y, Whitworth JA. Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2007; 20: 1222-8.
98. Iuchi T, Akaike M, Mitsui T, et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92: 81-7.
99. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-35.
100. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 1995; 268: H2274-80.
101. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci USA 1997; 94: 14483-8.
102. Wang HD, Pagano PJ, Du Y, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 1998; 82: 810-8.
103. Bengtsson SHM, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003; 30: 849-54.
104. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-97.
105. Groemping Y, Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem J 2005; 386: 401-16.
106. Heumuller S, Wind S, Barbosa-Sicard E, et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008; 51: 211-7.
107. Suzuki H, DeLano FA, Parks DA, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci USA 1998; 95: 4754-9.
108. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88: 10045-8.
109. Swei A, Lacy F, Delano FA, et al. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999; 6: 179-87.
110. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-5.
111. Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem J 2002; 362: 733-9.
112. Mitchell BM, Dorrance AM, Webb RC. GTP cyclohydrolase 1 downregulation contributes to glucocorticoid hypertension in rats. Hypertension 2003; 41: 669-74.
113. Schafer SC, Wallerath T, Closs EI, et al. Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles. Am J Physiol Heart Circ Physiol 2005; 288: H436-44.
114. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007; 100: 460-73.
115. Han D, Antunes F, Canali R, Rettori D, Cadenas E. Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 2003; 278: 5557-63.
116. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med 2005; 38: 1278-95.
117. Ramachandran A, Levonen A-L, Brookes PS, et al. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic Biol Med 2002; 33: 1465-74.
118. El Midaoui A, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003; 16: 173-9.
119. Ong SLH, Sutton M, Vohra H, Zhang Y, Whitworth JA. Alpha-lipoic acid prevents glucocorticoid-induced hypertension in the rat [Abstract]. J Hypertens 2008; 26: S76.
120. Cosentino F, Sill JC, Katusic ZS. Role of superoxide anions in the mediation of endothelium-dependent contractions. Hypertension 1994; 23: 229-35.
121. Kontos HA, Wei EP, Ellis EF, et al. Appearance of superoxide anion radical in cerebral extracellular space during increased prostaglandin synthesis in cats. Circ Res 1985; 57: 142-51.
122. Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159-65.
123. Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant Damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vasc Biol 2003; 23: 1345-51.
124. Siegal T, Soti F, Biegon A, Pop E, Brewster ME. Effect of a chemical delivery system for dexamethasone (Dex-CDS) on peritumoral edema in an experimental brain tumor model. Pharm Res 1997; 14: 672-5.
125. DBL Dexamethasone Sodium Phosphate Injection. Retrieved August 11, 2008, from MIMS Online.
126. Birmingham MK, Sar M, Stumpf WE. Dexamethasone target sites in the central nervous system and their potential relevance to mental illness. Cell Mol Neurobiol 1993; 13: 373-86.
127. Nakamoto H, Suzuki H, Kageyama Y, Murakami M, Naitoh M, Saruta T. Central nervous system mediates an antihypertensive property in glucocorticoid hypertension in dogs. J Hypertens 1995; 13: 1169-79.
128. Tonolo G, Soro A, Madeddu P, et al. Effect of chronic intracerebroventricular dexamethasone on blood pressure in normotensive rats. Am J Physiol Endocrinol Metab 1993; 264: E843-7.
129. Wang L-L, Ou C-C, Chan JYH. Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat. Mol Pharmacol 2005; 67: 489-98.
130. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987; 5: 425-33.
131. Whitworth JA, Saines D, Scoggins BA. Blood pressure and metabolic effects of cortisol and deoxycorticosterone in man. Clin Exp Hypertens A 1984; 6: 795-809.
132. Mangos GJ, Turner SW, Fraser TB, Whitworth JA. The role of corticosterone in corticotrophin (ACTH)-induced hypertension in the rat. J Hypertens 2000; 18: 1849-55.
133. Kelly JJ, Tam SH, Williamson PM, Lawson J, Whitworth JA. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 1998; 25: 945-6.
134. Scoggins BA, Allen KJ, Coghlan JP, et al. Haemodynamics of ACTH-induced hypertension in sheep. Clin Sci (Lond) 1979; 57 Suppl 5: 333s-6s.
135. Turner SW, Wen C, Li M, Fraser TB, Whitworth JA. Adrenocorticotrophin dose-response relationships in the rat: haemodynamic, metabolic and hormonal effects. J Hypertens 1998; 16: 593-600.
136. Whitworth JA. Adrenocorticotrophin and steroid-induced hypertension in humans. Kidney Int Suppl 1992; 37: S34-7.
137. Whitworth JA, Saines D, Scoggins BA. Potentiation of ACTH hypertension in man with salt loading. Clin Exp Pharmacol Physiol 1985; 12: 239-43.
138. Humphrey TJ, Fan JS, Coghlan JP, et al. Inter-relationships between sodium and potassium intake and the blood pressure effects of ACTH in sheep. J Hypertens 1983; 1: 19-26.
139. Connell JM, Whitworth JA, Davies DL, Richards AM, Fraser R. Haemodynamic, hormonal and renal effects of adrenocorticotrophic hormone in sodium-restricted man. J Hypertens 1988; 6: 17-23.
140. Mills EH, Coghlan JP, Denton DA, Spence CD, Whitworth JA, Scoggins BA. The effect of sodium depletion and potassium loading on cortisol induced hypertension in sheep. Acta Endocrinol (Copenh) 1986; 113: 298-304.
141. Zhang Y, Jang R, Mori TA, et al. The anti-oxidant Tempol reverses and partially prevents adrenocorticotrophic hormone-induced hypertension in the rat. J Hypertens 2003; 21: 1513-8.
142. Zhang Y, Chan MMK, Andrews MC, et al. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2005; 18: 910-6.
143. Wen C, Li M, Fraser T, Wang J, Turner SW, Whitworth JA. L-Arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. Blood Press 2000; 9: 298-304.
144. Turner SW, Mangos GJ, Whitworth JA. Nitric oxide synthase activity in adrenocorticotrophin-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2001; 28: 881-3.
145. Mondo CK, Yang W-S, Zhang N, Huang T-G. Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2006; 33: 1029-34.
146. Mondo CK, Zhang Y, Possamai VdM, et al. N-Acetylcysteine antagonizes the development but does not reverse ACTH-induced hypertension in the rat. Clin Exp Hypertens 2006; 28: 73-84.
147. Zhang Y, Pang T, Earl J, Schyvens CG, McKenzie KU, Whitworth JA. Role of tetrahydrobiopterin in adrenocorticotropic hormone-induced hypertension in the rat. Clin Exp Hypertens 2004; 26: 231-41.
148. Turner SW, Wen C, Li M, Whitworth JA. L-Arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996; 27: 184-9.
149. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131-85.
150. Shafagoj Y, Opoku J, Qureshi D, Regelson W, Kalimi M. Dehydroepiandrosterone prevents dexamethasone-induced hypertension in rats. Am J Physiol Endocrinol Metab 1992; 263: E210-3.
151. Li M, Wen C, Martin A, Whitworth JA. Dehydroepiandrosterone does not prevent adrenocorticotrophin-induced hypertension in conscious rats. Clin Exp Pharmacol Physiol 1996; 23: 435-7.
152. Kalimi M. Role of antiglucocorticoid RU 486 on dexamethasone-induced hypertension in rats. Am J Physiol Endocrinol Metab 1989; 256: E682-5.
153. Fraser TB, Turner SW, Wen C, Li M, Burrell LM, Whitworth JA. Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat. Clin Exp Pharmacol Physiol 2000; 27: 866-70.
154. Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994; 23: 737-43.
155. Fraillon D, Wynne KN, Funder JW. Further studies on neomycin and experimental hypertension. Clin Exp Pharmacol Physiol 1984; 11: 339-41.